Why it’s different
Simple to make. Advanced in care.
The value of Henley Ion sits in one contrast: a device built from a few simple, single-use parts that delivers treatment normally reserved for a clinic. Simple to produce; advanced in what it delivers.
The build
What it takes to make
A few simple, single-use parts — printed electrodes, coin cell, hydrogel, low-power driver.
Off-the-shelf, printable parts — no exotic supply chain.
No cold chain, no needles, no pump — stores and ships like a plaster.
Manufacturable at scale from off-the-shelf parts.
The care
What it does for patients
Fights infection, slows bleeding, manages pain from the moment it’s applied.
Needle-free, sub-dermal delivery — clinic-grade, on the skin.
Extends the golden hour to golden days of continuous treatment.
Reaches where care can’t — the field, the ER, remote and low-resource settings.
Why that ratio is the pitch
A device this simple to produce, delivering care this advanced, means strong margins, a large addressable market, and real human impact — the risk/reward a development partner looks for. And it’s de-risked: the same ionics platform is already prototyped and lab-validated at Tulane, grant-supported, and patent-protected.
Proven & de-risked
Not a concept — a platform with a track record
Tulane-validated: 99.8% of aerosolized SARS-CoV-2
LSU pre-clinical studies — needle-free anesthesia in ~4 min
Peer-reviewed in Viruses (2022)
Patented & patent-pending — incl. US 11,201,232 B2
NIH grant — TB-transmission control (mask work)
FDA-cleared predicate device — supports a 510(k) pathway
Current activity: SBIR Phase I proposals submitted for the wound bandage and CBRN mask.
Partner with us
The hard part is done. The scale-up is the opportunity.
Simple to build, advanced in care — and de-risked by lab validation, grant funding, and patents. The right partner takes it from here.
Start a conversation →